Selected research
Market Structure
Global Mental Disorders Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Mental Disorders Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Mental Disorders Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Mental Disorders Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Mental Disorders Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Mental Disorders Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Mental Disorders Drugs include Johnson & Johnson, Eli Lilly, Pfizer, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb and Abbott Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Mental Disorders Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Mental Disorders Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Mental Disorders Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Mental Disorders Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Mental Disorders Drugs Segment by Company
Johnson & Johnson
Eli Lilly
Pfizer
GlaxoSmithKline
AstraZeneca
Bristol-Myers Squibb
Abbott Laboratories
Mental Disorders Drugs Segment by Type
Drugs for Childhood and Adolescent Mental Illness
Drugs for Schizophrenia
Anxiolytics
Antipsychotics
Antidepressants
Sleep Disorders
Drugs to Treat Cognitive Disorders
Drugs for the Treatment of Substance and Alcohol Addiction
Others
Mental Disorders Drugs Segment by Application
Adolescents
Children
Adults
Mental Disorders Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mental Disorders Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mental Disorders Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mental Disorders Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Mental Disorders Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Mental Disorders Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Mental Disorders Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Mental Disorders Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Drugs for Childhood and Adolescent Mental Illness
- Drugs for Schizophrenia
- Anxiolytics
- Antipsychotics
- Antidepressants
- Sleep Disorders
- Drugs to Treat Cognitive Disorders
- Drugs for the Treatment of Substance and Alcohol Addiction
- Others
Applications
- Adolescents
- Children
- Adults
Companies covered
- Johnson & Johnson
- Eli Lilly
- Pfizer
- GlaxoSmithKline
- AstraZeneca
- Bristol-Myers Squibb
- Abbott Laboratories
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Mental Disorders Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Mental Disorders Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Mental Disorders Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Mental Disorders Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Mental Disorders Drugs Market Dynamics
- 2.1 Mental Disorders Drugs Industry Trends
- 2.2 Mental Disorders Drugs Industry Drivers
- 2.3 Mental Disorders Drugs Industry Opportunities and Challenges
- 2.4 Mental Disorders Drugs Industry Restraints
3 Mental Disorders Drugs Market by Manufacturers
- 3.1 Global Mental Disorders Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Mental Disorders Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Mental Disorders Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Mental Disorders Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Mental Disorders Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Mental Disorders Drugs Manufacturers, Product Type & Application
- 3.7 Global Mental Disorders Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Mental Disorders Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Mental Disorders Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Mental Disorders Drugs Tier 1, Tier 2, and Tier 3
4 Mental Disorders Drugs Market by Type
- 4.1 Mental Disorders Drugs Type Introduction
- 4.1.1 Drugs for Childhood and Adolescent Mental Illness
- 4.1.2 Drugs for Schizophrenia
- 4.1.3 Anxiolytics
- 4.1.4 Antipsychotics
- 4.1.5 Antidepressants
- 4.1.6 Sleep Disorders
- 4.1.7 Drugs to Treat Cognitive Disorders
- 4.1.8 Drugs for the Treatment of Substance and Alcohol Addiction
- 4.1.9 Others
- 4.2 Global Mental Disorders Drugs Sales by Type
- 4.2.1 Global Mental Disorders Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Mental Disorders Drugs Sales by Type (2021-2032)
- 4.2.3 Global Mental Disorders Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Mental Disorders Drugs Revenue by Type
- 4.3.1 Global Mental Disorders Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Mental Disorders Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Mental Disorders Drugs Revenue Market Share by Type (2021-2032)
5 Mental Disorders Drugs Market by Application
- 5.1 Mental Disorders Drugs Application Introduction
- 5.1.1 Adolescents
- 5.1.2 Children
- 5.1.3 Adults
- 5.2 Global Mental Disorders Drugs Sales by Application
- 5.2.1 Global Mental Disorders Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Mental Disorders Drugs Sales by Application (2021-2032)
- 5.2.3 Global Mental Disorders Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Mental Disorders Drugs Revenue by Application
- 5.3.1 Global Mental Disorders Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Mental Disorders Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Mental Disorders Drugs Revenue Market Share by Application (2021-2032)
6 Global Mental Disorders Drugs Sales by Region
- 6.1 Global Mental Disorders Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Mental Disorders Drugs Sales by Region (2021-2032)
- 6.2.1 Global Mental Disorders Drugs Sales by Region (2021-2026)
- 6.2.2 Global Mental Disorders Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Mental Disorders Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Mental Disorders Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Mental Disorders Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Mental Disorders Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Mental Disorders Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Mental Disorders Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Mental Disorders Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Mental Disorders Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Mental Disorders Drugs Revenue by Region
- 7.1 Global Mental Disorders Drugs Revenue by Region
- 7.1.1 Global Mental Disorders Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Mental Disorders Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Mental Disorders Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Mental Disorders Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Mental Disorders Drugs Revenue (2021-2032)
- 7.2.2 North America Mental Disorders Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Mental Disorders Drugs Revenue (2021-2032)
- 7.3.2 Europe Mental Disorders Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Mental Disorders Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Mental Disorders Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Mental Disorders Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Mental Disorders Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Johnson & Johnson
- 8.1.1 Johnson & Johnson Company Information
- 8.1.2 Johnson & Johnson Business Overview
- 8.1.3 Johnson & Johnson Mental Disorders Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Johnson & Johnson Mental Disorders Drugs Product Portfolio
- 8.1.5 Johnson & Johnson Recent Developments
- 8.2 Eli Lilly
- 8.2.1 Eli Lilly Company Information
- 8.2.2 Eli Lilly Business Overview
- 8.2.3 Eli Lilly Mental Disorders Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Eli Lilly Mental Disorders Drugs Product Portfolio
- 8.2.5 Eli Lilly Recent Developments
- 8.3 Pfizer
- 8.3.1 Pfizer Company Information
- 8.3.2 Pfizer Business Overview
- 8.3.3 Pfizer Mental Disorders Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Pfizer Mental Disorders Drugs Product Portfolio
- 8.3.5 Pfizer Recent Developments
- 8.4 GlaxoSmithKline
- 8.4.1 GlaxoSmithKline Company Information
- 8.4.2 GlaxoSmithKline Business Overview
- 8.4.3 GlaxoSmithKline Mental Disorders Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 GlaxoSmithKline Mental Disorders Drugs Product Portfolio
- 8.4.5 GlaxoSmithKline Recent Developments
- 8.5 AstraZeneca
- 8.5.1 AstraZeneca Company Information
- 8.5.2 AstraZeneca Business Overview
- 8.5.3 AstraZeneca Mental Disorders Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 AstraZeneca Mental Disorders Drugs Product Portfolio
- 8.5.5 AstraZeneca Recent Developments
- 8.6 Bristol-Myers Squibb
- 8.6.1 Bristol-Myers Squibb Company Information
- 8.6.2 Bristol-Myers Squibb Business Overview
- 8.6.3 Bristol-Myers Squibb Mental Disorders Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Bristol-Myers Squibb Mental Disorders Drugs Product Portfolio
- 8.6.5 Bristol-Myers Squibb Recent Developments
- 8.7 Abbott Laboratories
- 8.7.1 Abbott Laboratories Company Information
- 8.7.2 Abbott Laboratories Business Overview
- 8.7.3 Abbott Laboratories Mental Disorders Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Abbott Laboratories Mental Disorders Drugs Product Portfolio
- 8.7.5 Abbott Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Mental Disorders Drugs Value Chain Analysis
- 9.1.1 Mental Disorders Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Mental Disorders Drugs Production Mode & Process
- 9.2 Mental Disorders Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Mental Disorders Drugs Distributors
- 9.2.3 Mental Disorders Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst